Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation
International Journal of Molecular Sciences · 09.10.2023 · 24 (19) · 15019
DOI: 10.3390/ijms241915019 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.10.2023. Verfasst von Carmine Liberatore und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Oncology and Hematology, Santo Spirito Hospital, 65124 Pescara, Italy. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The management of patients with acute myeloid leukemia (AML) relapsed post allogeneic hematopoietic stem cell transplantation (HSCT) remains a clinical challenge. Intensive treatment approaches are limited by severe toxicities in the early post-transplantation period. Therefore, hypomethylating agents (HMAs) have become the standard therapeutic approach due to favorable tolerability. Moreover, HMAs serve as a backbone for additional anti-leukemic agents. Despite discordant results, the addition of donor lymphocytes infusions (DLI) generally granted improved outcomes with manageable GvHD incidence. The recent introduction of novel targeted drugs in AML gives the opportunity to add a third element to salvage regimens. Those patients harboring targetable mutations might benefit from IDH1/2 inhibitors Ivosidenib and Enasidenib as well as FLT3 inhibitors Sorafenib and Gilteritinib in combination with HMA and DLI. Conversely, patients lacking targetable mutations actually benefit from the addition of Venetoclax. A second HSCT remains a valid option, especially for fit patients and for those who achieve a complete disease response with salvage regimens. Overall, across studies, higher response rates and longer survival were observed in cases of pre-emptive intervention for molecular relapse. Future perspectives currently rely on the development of adoptive immunotherapeutic strategies mainly represented by CAR-T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, Department of Oncology and Hematology, Santo Spirito Hospital, 65124 Pescara, Italy.
- Department of Medicine and Sciences of Aging, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
ORCID-Profile: Carmine Liberatore, Mauro Di Ianni
Zitieren
APA
Liberatore, C., & Di Ianni, M. (2023). Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation. International Journal of Molecular Sciences, 24(19), 15019. https://doi.org/10.3390/ijms241915019
Vancouver
Liberatore C, Di Ianni M. Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation. International Journal of Molecular Sciences. 2023;24(19):15019. doi:10.3390/ijms241915019
BibTeX
@article{Liberatore2023,
author = {Liberatore, Carmine and Di Ianni, Mauro},
title = {Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {19},
pages = {15019},
doi = {10.3390/ijms241915019}
}
EUVIMED